etopophos etoposide phosphate 113.6mg (equivalent to 100mg etoposide) powder for injection vial
link medical products pty ltd t/a link pharmaceuticals - etoposide phosphate, quantity: 113.6 mg - injection, powder for - excipient ingredients: sodium citrate dihydrate; dextran 40 - for use in the treatment of: small cell carcinoma of the lung; acute monocytic and myelomonocytic leukaemia; hodgkin's disease; non- hodgkin's lymphoma and testicular tumours.
vepesid etoposide 100mg capsule blister pack
link medical products pty ltd t/a link pharmaceuticals - etoposide, quantity: 100 mg - capsule - excipient ingredients: iron oxide red; gelatin; purified water; glycerol; sodium propyl hydroxybenzoate; citric acid; sodium ethyl hydroxybenzoate; titanium dioxide; macrogol 400 - 1 - small cell carcinoma of the lung 2 - acutre monocytic and myelomoncytic leukaemia 3 - hodgkins disease 4 - non-hodgkins lymphoma indications as at 5 october 2000: in the treatment of: 1. small cell carcinoma of the lung. 2. acute monocytic and myelomonocytic leukaemia. 3. hodgkin's disease. 4. non-hodgkin's lymphoma.
vepesid etoposide 50mg capsule blister pack
link medical products pty ltd t/a link pharmaceuticals - etoposide, quantity: 50 mg - capsule - excipient ingredients: sodium propyl hydroxybenzoate; glycerol; sodium ethyl hydroxybenzoate; citric acid; iron oxide red; gelatin; titanium dioxide; macrogol 400; purified water - 1 - small cell carcinoma of the lung 2 - acute monocytic and myelomonocytic leukaemia 3 - hodgkins disease 4 - non-hodgkins lymphonia indications as at 5 october 2000: in the treatment of: 1. small cell carcinoma of the lung. 2. acute monocytic and myelomonocytic leukaemia. 3. hodgkin's disease. 4. non-hodgkin's lymphoma.
amitriptyline hydrochloride 25 mg/ 5 ml oral solution
pinewood laboratories ltd, - amitriptyline hydrochloride - oral solution - 25 mg/5ml - non-selective monoamine reuptake inhibitors; amitriptyline
amitriptyline hydrochloride 50 mg/ 5 ml oral solution
pinewood laboratories ltd, - amitriptyline hydrochloride - oral solution - 50 mg/5ml - non-selective monoamine reuptake inhibitors; amitriptyline
john plunkett's eczema cream
sunspot products pty ltd - aloe vera,borago officinalis,matricaria chamomilla,natural fish oil -
john o'neill's advanced co-enzyme q10-150mg
advanced life products pty ltd - magnesium phosphate pentahydrate,ubidecarenone -
john plunkett's superfade uv day shield spf 30+
sunspot products pty ltd - octyl methoxycinnamate,oxybenzone,titanium dioxide -
john plunkett?s superfade face treatment cream tube
sunspot products pty ltd - salicylic acid, quantity: 15 mg/g; hydroquinone, quantity: 20 mg/g; padimate o, quantity: 30 mg/g - cream - excipient ingredients: dexpanthenol; butylated hydroxyanisole; sodium sulfite; cetostearyl alcohol; white soft paraffin; dl-alpha-tocopheryl acetate; purified water; liquid paraffin; chlorocresol; citric acid; sodium metabisulfite; propylene glycol; sodium lauryl sulfate; glycerol; cetomacrogol 1000; glyceryl monostearate; peg-100 stearate - to assist in fading brown skin blemishes including freckles and agespots.
john plunkett's superfade treatment cream tube
sunspot products pty ltd - padimate o, quantity: 30 mg/g; hydroquinone, quantity: 20 mg/g; salicylic acid, quantity: 15 mg/g - cream - excipient ingredients: chlorocresol; sodium metabisulfite; citric acid; propylene glycol; cetostearyl alcohol; light liquid paraffin; white soft paraffin; dexpanthenol; sodium sulfite; purified water; glycerol; sodium lauryl sulfate; dl-alpha-tocopheryl acetate; cetomacrogol 1000; butylated hydroxyanisole; glyceryl monostearate; peg-100 stearate - to assist in fading age spots, freckles and brown skin blemishes. age spots, freckles and brown skin blemishes occur when areas of excessive pigmentation cause irregular brown marks on skin, especially on backs of hands, arms, neck and face. superfade cream contains a powerful fading agent and other ingredients to assist in fading age spots freckles and brown skin blemishes. the cream works gradually and results should begin to appear after 6 weeks.